Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies?

被引:0
|
作者
Massimo Papale
Salvatore Di Paolo
Grazia Vocino
Maria Teresa Rocchetti
Loreto Gesualdo
机构
[1] University of Bari “Aldo Moro”,Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O)
[2] University of Foggia,Core Facility of Proteomics and Mass Spectrometry, Department of Surgery and Medical Sciences
[3] “Dimiccoli” Hospital,Nephrology Unit
来源
Journal of Nephrology | 2014年 / 27卷
关键词
Diabetic nephropathy; Proteome; Proteomics; Urine; Tissues; Biomarkers;
D O I
暂无
中图分类号
学科分类号
摘要
Diabetic nephropathy (DN) has become the most frequent cause of chronic kidney disease worldwide due to the constant increase of the incidence of type 2 diabetes mellitus in developed and developing countries. The understanding of the pathophysiological mechanisms of human diseases through a large-scale characterization of the protein content of a biological sample is the key feature of the proteomics approach to the study of human disease. We discuss the main results of over 10 years of tissue and urine proteomics studies applied to DN in order to understand how far we have come and how far we still have to go before obtaining a full comprehension of the molecular mechanisms involved in the pathogenesis of DN and identifying reliable biomarkers for accurate management of patients.
引用
收藏
页码:221 / 228
页数:7
相关论文
共 50 条
  • [1] Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies?
    Papale, Massimo
    Di Paolo, Salvatore
    Vocino, Grazia
    Rocchetti, Maria Teresa
    Gesualdo, Loreto
    JOURNAL OF NEPHROLOGY, 2014, 27 (03) : 221 - 228
  • [2] Erratum to: Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies?
    Massimo Papale
    Salvatore Di Paolo
    Grazia Vocino
    Maria Teresa Rocchetti
    Loreto Gesualdo
    Journal of Nephrology, 2014, 27 : 465 - 466
  • [3] Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies? (vol 27, pg 221, 2014)
    Papale, Massimo
    Di Paolo, Salvatore
    Vocino, Grazia
    Rocchetti, Maria Teresa
    Gesualdo, Loreto
    JOURNAL OF NEPHROLOGY, 2014, 27 (04) : 465 - 466
  • [4] PATHOGENESIS AND TREATMENT OF DIABETIC NEPHROPATHY, WHAT WE HAVE LEARNED FROM PROTEOMICS AND miRNA
    Fan Qiuling
    Wang Lining
    NEPHROLOGY, 2014, 19 : 5 - 5
  • [5] Proteomics dedicated to biofilmology: What have we learned from a decade of research?
    Khemiri, Arbia
    Jouenne, Thierry
    Cosette, Pascal
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2016, 205 (01) : 1 - 19
  • [6] Proteomics dedicated to biofilmology: What have we learned from a decade of research?
    Arbia Khemiri
    Thierry Jouenne
    Pascal Cosette
    Medical Microbiology and Immunology, 2016, 205 : 1 - 19
  • [7] HIV and Proteomics: What We Have Learned from High Throughput Studies
    Grabowska, Kinga
    Harwood, Emma
    Ciborowski, Pawel
    PROTEOMICS CLINICAL APPLICATIONS, 2021, 15 (01)
  • [8] Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
    Chugh, Shaan
    Suen, Colin
    Gramolini, Anthony
    CURRENT CARDIOLOGY REVIEWS, 2010, 6 (02) : 124 - 133
  • [9] What have we learned from the other omics: Transcriptomics, proteomics, lipidomics, as compared to genomics
    Laurence, Steinman
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 228 (1-2) : 69 - 69
  • [10] A DECADE OF STUDIES OF HUMAN EXPOSURE - WHAT HAVE WE LEARNED
    WALLACE, L
    RISK ANALYSIS, 1993, 13 (02) : 135 - 139